

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2016/0003862				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
PALABRAS CLAVE UTILIZADAS		Trail, tnf, fusion protein, agonist, fc		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K 14/705, A61K 38/00, A61K 38/19.		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	NA			
ISA/IPEA (EPO) EPO LENS (seq 19)	WO2010010051	28/01/2010	NA	A
EPODOC	US20110027218	03/02/2011	NA	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	
---	--

Fecha del reporte de búsqueda:	07/03/2018
--------------------------------	------------

Base de datos	NCBI
QUERY	SEQ 19

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Fc IgG1 heavy chain constant region [Homo sapiens]	485	485	30%	1e-165	99%	AEV43323.1
☐	recombinant IgG1 heavy chain [Homo sapiens]	488	488	30%	4e-165	99%	AAG00909.1
☐	immunoglobulin heavy chain [Homo sapiens]	488	488	30%	4e-165	99%	AEL33691.1
☐	Hepatitis B virus receptor binding protein [Homo sapiens]	488	488	30%	9e-165	99%	AAS88328.1
☐	immunoglobulin heavy chain [Homo sapiens]	489	489	30%	6e-164	99%	ARA90394.1
☐	humanized murine anti-VEEV antibody Hy4-26C heavy chain [synthetic construct]	489	489	30%	7e-164	99%	ABH10632.1
☐	immunoglobulin heavy chain [Homo sapiens]	489	489	30%	8e-164	99%	ARA90387.1
☐	anti-rabies SOJA immunoglobulin heavy chain [Homo sapiens]	490	490	30%	9e-164	99%	AAO17823.1
☐	immunoglobulin heavy chain [Homo sapiens]	489	489	30%	9e-164	99%	ARA90396.1
☐	IGHM [synthetic construct]	490	490	30%	1e-163	99%	AIC63052.1
☐	chimeric anti-human type VII collagen immunoglobulin G1 [synthetic construct]	489	489	30%	1e-163	99%	ACN59874.1
☐	unnamed protein product [Homo sapiens]	489	489	30%	1e-163	99%	BAC85199.1
☐	unnamed protein product [Homo sapiens]	489	489	30%	1e-163	99%	BAC85373.1

Base de datos	NCBI
QUERY	SEQ 16

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Synthetic construct erythropoietin-IgG1 fusion protein codon gene, complete cds	771	771	29%	0.0	88%	KC329647.1
☐	Synthetic construct Leu16-28-z gene, complete cds	769	769	29%	0.0	88%	KX055829.1
☐	Synthetic construct Leu16-28-BB-z-2A-1EGFR gene, complete cds	769	769	29%	0.0	88%	KX055828.1
☐	Synthetic construct bi-specific chimeric antigen receptor 20-19 Long gene, partial cds	769	769	29%	0.0	88%	KX000907.1
☐	Synthetic construct bi-specific chimeric antigen receptor 19-20 Long gene, partial cds	769	769	29%	0.0	88%	KX000905.1
☐	Synthetic construct Bevacizumab heavy chain gene, complete cds	549	549	30%	1e-151	82%	KX119517.1
☐	Camelus bactrianus immunoglobulin IgG3 heavy chain constant region mRNA, partial cds	267	267	29%	2e-66	74%	KP999950.1
☐	Camelus bactrianus immunoglobulin IgG1a heavy chain constant region mRNA, partial cds	263	263	29%	2e-65	74%	KP999946.1
☐	C.dromedarius mRNA for immunoglobulin, gamma chain	261	261	29%	7e-65	74%	Z48947.1
☐	Camelus dromedarius partial mRNA for immunoglobulin gamma 1a heavy chain (IGHC2/C3	250	250	28%	2e-61	74%	HE653095.1
☐	Camelus dromedarius partial mRNA for immunoglobulin heavy chain constant region of (IGC	250	250	28%	2e-61	74%	AJ421266.1
☐	Camelus bactrianus immunoglobulin IgG2c heavy chain constant region mRNA, partial cds	244	244	29%	7e-60	74%	KP999949.1
☐	Camelus bactrianus immunoglobulin IgG2a heavy chain constant region mRNA, partial cds	235	235	29%	4e-57	74%	KP999948.1

[EPODOC: SS 5] ..er all

[SS 1] trail and tnf

Results in EPODOC 233

[SS 2] 1 and agonist

Results in EPODOC 6

[SS 3] 2 and pd<20140323

[SS 4] 1 and fusion

Results in EPODOC 19

5/8 © EPODOC / EPO																																					
TI	- (A B) TNF (Tumor Necrosis Factor)-related apoptosis-inducing ligand fusion protein and preparation method thereof																																				
PN	- CN102775497 A 20121114																																				
6/8 © EPODOC / EPO																																					
TI	- (A1) TNF SUPERFAMILY FUSION PROTEINS - (B2) CD95L or trail fusion proteins																																				
PN	- US2011027218 A1 20110203																																				
Figure 3 Cellular Apoptosis Assay with Jurkat Cells: Impact of CD95 Ligand (hs95L-A14, Different SEC Fractions) on Caspase Activity <table border="1"> <caption>Approximate data for Figure 3</caption> <thead> <tr> <th>Fraction</th> <th>Relative Caspase Activity</th> </tr> </thead> <tbody> <tr><td>E3</td><td>0</td></tr> <tr><td>E4</td><td>0</td></tr> <tr><td>E5</td><td>0</td></tr> <tr><td>E6</td><td>0</td></tr> <tr><td>E7</td><td>0</td></tr> <tr><td>E8</td><td>0</td></tr> <tr><td>E9</td><td>0</td></tr> <tr><td>E10</td><td>10</td></tr> <tr><td>E11</td><td>70</td></tr> <tr><td>E12</td><td>90</td></tr> <tr><td>E13</td><td>90</td></tr> <tr><td>E14</td><td>75</td></tr> <tr><td>E15</td><td>10</td></tr> <tr><td>C1</td><td>0</td></tr> <tr><td>C2</td><td>0</td></tr> <tr><td>C3</td><td>0</td></tr> <tr><td>C4</td><td>0</td></tr> </tbody> </table>		Fraction	Relative Caspase Activity	E3	0	E4	0	E5	0	E6	0	E7	0	E8	0	E9	0	E10	10	E11	70	E12	90	E13	90	E14	75	E15	10	C1	0	C2	0	C3	0	C4	0
Fraction	Relative Caspase Activity																																				
E3	0																																				
E4	0																																				
E5	0																																				
E6	0																																				
E7	0																																				
E8	0																																				
E9	0																																				
E10	10																																				
E11	70																																				
E12	90																																				
E13	90																																				
E14	75																																				
E15	10																																				
C1	0																																				
C2	0																																				
C3	0																																				
C4	0																																				
PN	- US2010199364 A1 20100805																																				
7/8 © EPODOC / EPO																																					
TI	- (A1) TNF SUPERFAMILY COLLECTIN FUSION PROTEINS - (B2) Collectin fusion proteins comprising TNF or trail																																				
PN	- US2010199364 A1 20100805																																				
8/8 © EPODOC / EPO																																					
TI	- FUSION PROTEIN COMPRISING A TNF RELATED APOPTOSIS INDUCING LIGAND (TRAIL) PEPTIDE AND ITS PREPARATION																																				
PN	- IL184699 A 20111130																																				

Base de datos	LENS-FINDER			
QUERY	SEQ 19			
Patent Number	Title	Publication Date	SEQ ID NO	Local % Id
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	43	98.4%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	43	98.4%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	43	98.4%
JP 2011528562 A		24/11/11	47	98.4%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	43	98.4%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	43	98.4%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	43	98.4%
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	45	99.6%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	45	99.6%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	45	99.6%
JP 2011528562 A		24/11/11	48	99.6%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	45	99.6%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	45	99.6%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	45	99.6%
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	28	98.8%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	28	98.8%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	28	98.8%
JP 2011528562 A		24/11/11	37	98.8%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	28	98.8%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	28	98.8%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	28	98.8%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	126	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	126	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	128	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	128	89.9%
WO 2013 156054 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	14	89.9%
CA 2870217 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	14	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	125	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	125	89.9%
WO 2013 041730 A1	SERUM HALF-LIFE EXTENSION USING	28/03/13	15	89.9%
CA 2846436 A1	SERUM HALF-LIFE EXTENSION USING	28/03/13	15	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	129	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	129	89.9%
WO 2013 156054 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	17	89.9%
CA 2870217 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	17	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	104	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	104	89.9%
WO 2013 156054 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	6	89.9%

CA 2870217 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	6	89.9%
WO 2013 156054 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	16	89.9%
CA 2870217 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	16	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	107	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	107	89.9%
WO 2013 156054 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	13	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	96	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	96	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	103	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	103	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	97	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	97	89.9%
CA 2870217 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	13	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	98	87.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	98	87.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	102	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	102	89.9%
WO 2012 130471 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	127	89.9%
CA 2831820 A1	POLYPEPTIDES WITH ANTIBODY BINDING DOMAIN AND USES THEREOF	04/10/12	127	89.9%
WO 2013 156054 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	12	89.9%
CA 2870217 A1	COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY	24/10/13	12	89.9%
JP 2007530021 A		01/11/07	39	87.3%
WO 2005 103077 A1	RECOMBINANT POLYPEPTIDES OF THE MEMBERS OF THE TNF LIGAND FAMILY AND USE THEREOF	03/11/05	38	87.3%
JP 2007530021 A		01/11/07	36	87.3%
WO 2005 103077 A1	RECOMBINANT POLYPEPTIDES OF THE MEMBERS OF THE TNF LIGAND FAMILY AND USE THEREOF	03/11/05	32	87.3%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	6	94.4%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	9	94.6%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	11	94.6%

US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	5	94.6%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	10	93.5%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	8	94.6%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	7	93.5%
US 2013 0302270 A1	INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR	14/11/13	12	93.5%
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	51	96.4%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	51	96.4%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	51	96.4%
JP 2011528562 A		24/11/11	51	96.4%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	51	96.4%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	51	96.4%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	51	96.4%
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	29	95.6%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	29	95.6%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	29	95.6%
JP 2011528562 A		24/11/11	38	95.6%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	29	95.6%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	29	95.6%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	29	95.6%
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	49	96.%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	49	96.%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	49	96.%
JP 2011528562 A		24/11/11	50	96.%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	49	96.%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	49	96.%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	49	96.%
US 2011 0162095 A1	TNFSF Single Chain Molecules	30/06/11	47	96.4%
US 2014 0056843 A1	TNFSF SINGLE CHAIN MOLECULES	27/02/14	47	96.4%
US 8450460 B2	Single-chain TNFSF fusion polypeptides	28/05/13	47	96.4%
JP 2011528562 A		24/11/11	49	96.4%
WO 2010 010051 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	47	96.4%
CA 2731388 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	47	96.4%
CA 2910512 A1	TNFSF SINGLE CHAIN MOLECULES	28/01/10	47	96.4%
US 2010 0303811 A1	and use thereof for inducing enhancement or repression of antigen-specific immunity.	02/12/10	14	53.5%
US 2011 0243944 A1	Preparation Method and Medicine Compositions Thereof	06/10/11	2	71.8%
US 8460673 B2	preparation method and medicine compositions thereof	11/06/13	2	71.8%
WO 2010 043153 A1	FORMATION, PREPARATION METHOD AND DRUG COMPOSITIONS THEREOF	22/04/10	2	71.8%
US 2010 0303811 A1	and use thereof for inducing enhancement or repression of antigen-specific immunity.	02/12/10	42	67.7%
US 2010 0303811 A1	and use thereof for inducing enhancement or repression of antigen-specific immunity.	02/12/10	38	67.9%
US 2009 0232808 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	17/09/09	190	67.6%
JP 2008528006 A		31/07/08	199	67.6%
CA 2596537 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	03/08/06	190	67.6%
US 2013 0211051 A1	FUSION PROTEIN CONTAINING VEGI, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF	15/08/13	5	66.4%
US 2010 0303811 A1	and use thereof for inducing enhancement or repression of antigen-specific immunity.	02/12/10	12	67.7%
US 2010 0303811 A1	and use thereof for inducing enhancement or repression of antigen-specific immunity.	02/12/10	18	67.7%
US 2009 0232808 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	17/09/09	38	68.9%
JP 2008528006 A		31/07/08	130	68.9%
CA 2596537 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	03/08/06	38	68.9%

US 2009 0232808 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	17/09/09	40	68.9%
JP 2008528006 A		31/07/08	131	68.9%
CA 2596537 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	03/08/06	40	68.9%
US 2009 0232808 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	17/09/09	54	64.9%
JP 2008528006 A		31/07/08	138	64.9%
CA 2596537 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	03/08/06	54	64.9%
US 2009 0232808 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	17/09/09	56	64.9%
JP 2008528006 A		31/07/08	139	64.9%
CA 2596537 A1	MOLECULES AND CHIMERIC MOLECULES THEREOF	03/08/06	56	64.9%
US 2010 0303811 A1	and use thereof for inducing enhancement or repression of antigen-specific immunity.	02/12/10	8	66.6%